CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:5CV - NL0015436031 - Common Stock
3.892 EUR
+0.01 (+0.36%)
5CV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. 5CV has only an average score on both its financial health and profitability. 5CV is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- 5CV had positive earnings in the past year.
- In the past year 5CV has reported a negative cash flow from operations.
- 5CV had negative earnings in 4 of the past 5 years.
- In multiple years 5CV reported negative operating cash flow during the last 5 years.
1.2 Ratios
- 5CV's Return On Assets of 11.31% is amongst the best of the industry. 5CV outperforms 84.34% of its industry peers.
- With an excellent Return On Equity value of 14.79%, 5CV belongs to the best of the industry, outperforming 84.34% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 14.12%, 5CV belongs to the top of the industry, outperforming 87.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROIC | 14.12% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 182.11%, 5CV belongs to the top of the industry, outperforming 98.80% of the companies in the same industry.
- With an excellent Operating Margin value of 212.01%, 5CV belongs to the best of the industry, outperforming 98.80% of the companies in the same industry.
- Looking at the Gross Margin, with a value of 93.01%, 5CV belongs to the top of the industry, outperforming 86.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 5CV is creating value.
- 5CV has about the same amout of shares outstanding than it did 1 year ago.
- 5CV has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, 5CV has an improved debt to assets ratio.
2.2 Solvency
- 5CV has an Altman-Z score of 4.17. This indicates that 5CV is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 4.17, 5CV is in the better half of the industry, outperforming 75.90% of the companies in the same industry.
- 5CV has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
- 5CV has a better Debt to Equity ratio (0.03) than 69.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.17 |
ROIC/WACC1.96
WACC7.19%
2.3 Liquidity
- A Current Ratio of 3.70 indicates that 5CV has no problem at all paying its short term obligations.
- With a decent Current ratio value of 3.70, 5CV is doing good in the industry, outperforming 69.88% of the companies in the same industry.
- A Quick Ratio of 3.69 indicates that 5CV has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.69, 5CV is in the better half of the industry, outperforming 73.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 20.83% over the past year.
- The Revenue for 5CV has decreased by -86.98% in the past year. This is quite bad
- Measured over the past years, 5CV shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
3.2 Future
- The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
- 5CV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.14% yearly.
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 6.71, the valuation of 5CV can be described as very cheap.
- 5CV's Price/Earnings ratio is rather cheap when compared to the industry. 5CV is cheaper than 95.18% of the companies in the same industry.
- When comparing the Price/Earnings ratio of 5CV to the average of the S&P500 Index (27.47), we can say 5CV is valued rather cheaply.
- The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.71 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 5CV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 5CV is cheaper than 96.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.92 |
4.3 Compensation for Growth
- A cheap valuation may be justified as 5CV's earnings are expected to decrease with -28.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
- No dividends for 5CV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:5CV (1/5/2026, 7:00:00 PM)
3.892
+0.01 (+0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24 2025-11-24/bmo
Earnings (Next)04-08 2026-04-08/amc
Inst Owners10.45%
Inst Owner ChangeN/A
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap876.36M
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts74.55
Price Target4.02 (3.29%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)557.4%
Min EPS beat(2)-39.67%
Max EPS beat(2)1154.47%
EPS beat(4)2
Avg EPS beat(4)282.88%
Min EPS beat(4)-39.67%
Max EPS beat(4)1154.47%
EPS beat(8)3
Avg EPS beat(8)141.82%
EPS beat(12)5
Avg EPS beat(12)87.36%
EPS beat(16)8
Avg EPS beat(16)76.39%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)-2.38%
PT rev (3m)-4.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)404.74%
EPS NY rev (1m)9.31%
EPS NY rev (3m)2.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)34.82%
Revenue NY rev (1m)19.7%
Revenue NY rev (3m)20.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.71 | ||
| Fwd PE | N/A | ||
| P/S | 12.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.01 | ||
| P/tB | 1.04 | ||
| EV/EBITDA | 2.92 |
EPS(TTM)0.58
EY14.9%
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.31
BVpS3.87
TBVpS3.76
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROCE | 16.62% | ||
| ROIC | 14.12% | ||
| ROICexc | 26.37% | ||
| ROICexgc | 27.79% | ||
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% | ||
| FCFM | N/A |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 28.09% | ||
| Cap/Sales | 7.01% | ||
| Interest Coverage | 66.45 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z | 4.17 |
F-Score3
WACC7.19%
ROIC/WACC1.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / 5CV.DE FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 4 / 10 to 5CV.DE.
What is the valuation status of CUREVAC NV (5CV.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (5CV.DE). This can be considered as Overvalued.
Can you provide the profitability details for CUREVAC NV?
CUREVAC NV (5CV.DE) has a profitability rating of 5 / 10.
What are the PE and PB ratios of CUREVAC NV (5CV.DE) stock?
The Price/Earnings (PE) ratio for CUREVAC NV (5CV.DE) is 6.71 and the Price/Book (PB) ratio is 1.01.
How financially healthy is CUREVAC NV?
The financial health rating of CUREVAC NV (5CV.DE) is 6 / 10.